Metastatic Solid Tumours

Drug	Drug Name	Drug Description
DB08912	Dabrafenib	A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.

Drug	Drug Name	Target	Type
DB08912	Dabrafenib	Cytochrome P450 3A4	enzyme
DB08912	Dabrafenib	Cytochrome P450 2C8	enzyme
DB08912	Dabrafenib	P-glycoprotein 1	transporter
DB08912	Dabrafenib	ATP-binding cassette sub-family G member 2	transporter
DB08912	Dabrafenib	Solute carrier organic anion transporter family member 1B1	transporter
DB08912	Dabrafenib	Solute carrier organic anion transporter family member 1B3	transporter
DB08912	Dabrafenib	Solute carrier family 22 member 6	transporter
DB08912	Dabrafenib	Solute carrier family 22 member 8	transporter
DB08912	Dabrafenib	Serine/threonine-protein kinase B-raf	target
DB08912	Dabrafenib	RAF proto-oncogene serine/threonine-protein kinase	target
DB08912	Dabrafenib	Serine/threonine-protein kinase SIK1	target
DB08912	Dabrafenib	Serine/threonine-protein kinase Nek11	target
DB08912	Dabrafenib	LIM domain kinase 1	target
DB08912	Dabrafenib	Cytochrome P450 2B6	enzyme
DB08912	Dabrafenib	Cytochrome P450 2C9	enzyme
DB08912	Dabrafenib	Cytochrome P450 2C19	enzyme
DB08912	Dabrafenib	Cytochrome P450 1A2	enzyme
DB08912	Dabrafenib	Serum albumin	carrier
DB08912	Dabrafenib	Solute carrier organic anion transporter family member 1A2	transporter
DB08912	Dabrafenib	Solute carrier family 22 member 2	transporter
DB08912	Dabrafenib	UDP-glucuronosyltransferase 1-1	enzyme

Drug	Drug Name	Phase	Status	Count
DB11740	Adavosertib	1	Completed	1